ALZN Stock Price, Alzamend Neuro, Inc. Quote, Chart

Market Summary

USD0.71-0.02

Market Closed

-2.74%

ALZN Stock Price

View Fullscreen

ALZN RSI Chart

ALZN Valuation

Market Cap

4.9M

Price/Earnings (Trailing)

-0.39

Price/Free Cashflow

-0.54

ALZN Price/Earnings (Trailing)

ALZN Profitability

Return on Equity

290.86%

Return on Assets

-1.6K%

Free Cashflow Yield

-186.21%

ALZN Fundamentals

ALZN Earnings

Earnings (TTM)

-12.4M

Earnings Growth (Yr)

50.93%

Earnings Growth (Qtr)

8.38%

Breaking Down ALZN Revenue

Last 7 days

-1.4%

Last 30 days

-29.7%

Last 90 days

-21.1%

Trailing 12 Months

26.8%

How does ALZN drawdown profile look like?

ALZN Financial Health

Current Ratio

0.16

ALZN Investor Care

Buy Backs (1Y)

92.62%

Diluted EPS (TTM)

-1.9

Tracking the Latest Insider Buys and Sells of Alzamend Neuro, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 19, 2024	ault milton c iii	bought	688	0.6882	1,000	-
Apr 01, 2024	ault milton c iii	bought	304	0.9109	334	-
Jan 23, 2024	ault milton c iii	sold	-	-	-661,168	-
Jan 05, 2024	ault milton c iii	bought	2,127	1.0635	2,000	-
Jan 05, 2024	ault milton c iii	bought	5,092	1.0185	5,000	-
Dec 26, 2023	ault milton c iii	bought	450	0.9	500	-
Dec 22, 2023	ault milton c iii	bought	184	0.9242	200	-
Sep 26, 2023	katzoff david j	bought	10,234	0.1931	53,000	chief financial officer
May 24, 2023	ault milton c iii	bought	10,704	0.5947	18,000	-
Apr 28, 2023	jackman stephan	bought	19,998	0.5405	37,000	chief executive officer

Which funds bought or sold ALZN recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 12, 2024	HARBOR INVESTMENT ADVISORY, LLC	unchanged	-	22.00	200	-%
Apr 11, 2024	RFG Advisory, LLC	unchanged	-	1,833	16,666	-%
Mar 11, 2024	VANGUARD GROUP INC	sold off	-100	-482,355	-	-%
Mar 11, 2024	VANGUARD GROUP INC	new	-	69,905	69,905	-%
Feb 14, 2024	BANK OF AMERICA CORP /DE/	new	-	42.00	42.00	-%
Feb 14, 2024	MILLENNIUM MANAGEMENT LLC	sold off	-100	-6,548	-	-%
Feb 14, 2024	TWO SIGMA SECURITIES, LLC	sold off	-100	-6,673	-	-%
Feb 14, 2024	STATE STREET CORP	sold off	-100	-7,560	-	-%
Feb 13, 2024	MORGAN STANLEY	new	-	29.00	29.00	-%
Feb 13, 2024	RENAISSANCE TECHNOLOGIES LLC	new	-	9,000	9,000	-%

Are Funds Buying or Selling ALZN?

Are funds buying ALZN calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ALZN

No. of Funds

Unveiling Alzamend Neuro, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 02, 2024	ault milton c iii	40.3%	3,158,036	SC 13D/A
Jan 25, 2024	ault milton c iii	29.4%	1,938,036	SC 13D/A
Nov 15, 2022	ault milton c iii	43.2%	43,821,652	SC 13D/A
Apr 28, 2022	ault milton c iii	43.2%	42,368,318	SC 13D/A

Recent SEC filings of Alzamend Neuro, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 23, 2024	4	Insider Trading
Apr 03, 2024	4	Insider Trading
Apr 01, 2024	4	Insider Trading
Mar 29, 2024	8-K	Current Report
Mar 28, 2024	4	Insider Trading
Mar 25, 2024	DEF 14A	DEF 14A
Mar 25, 2024	10-Q	Quarterly Report
Mar 22, 2024	8-K	Current Report
Mar 18, 2024	NT 10-Q	NT 10-Q
Mar 13, 2024	PRE 14A	PRE 14A

Peers (Alternatives to Alzamend Neuro, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.6B	6.8B	-1.39%	-19.31%	-8.82	6.07	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.1B	1.8B	-5.44%	-28.86%	-41.14	9.91	76.23%	61.08%
BMRN	17.2B	2.4B	5.41%	-4.57%	102.64	7.11	15.42%	18.43%
INCY	11.6B	3.7B	-9.99%	-29.65%	19.44	3.14	8.87%	75.42%
MID-CAP
APLS	6.0B	396.6M	-10.10%	-42.90%	-11.39	15.18	425.83%	18.94%
BBIO	4.4B	-	-14.83%	70.74%	-6.74	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-7.99%	-0.08%	-14.09	12.46	440.80%	-27.84%
ARWR	2.9B	240.7M	-16.49%	-30.64%	-9.72	12.18	-1.03%	-92.09%
ACAD	2.7B	726.4M	-7.01%	-17.50%	-44.6	3.76	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-4.67%	-6.03%	24.96	4.48	85.90%	-14.05%
NVAX	580.8M	983.7M	-13.72%	-45.61%	-1.07	0.59	-50.36%	17.16%
CRBP	372.9M	881.7K	-0.25%	294.45%	-8.36	466.16	-77.61%	-5.33%
INO	237.4M	4.9M	-18.06%	3.25%	-1.76	48.79	-54.97%	51.71%
IBIO	6.6M	2.1M	70.91%	57.98%	-0.24	2.14	-13.45%	66.37%

Alzamend Neuro, Inc. News

Latest updates

Alzamend Neuro, Inc. Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet													(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2020Q2
Assets	-20.4%	783	984	2,628	5,916	8,502	10,425	12,210	14,516	12,429	14,501	16,818	2,913	1,814
Current Assets	-24.1%	594	782	2,414	5,836	8,417	10,334	12,115	14,414	12,429	14,501	16,818	2,913	1,814
Cash Equivalents	41.4%	283	200	1,695	5,141	7,376	9,183	11,527	14,064	11,790	13,573	15,618	1,929	90.00
Net PPE	-6.3%	189	202	214	80.00	85.00	90.00	96.00	103	-	-	-	-	-
Liabilities	24.6%	4,569	3,666	2,741	2,870	2,642	1,637	1,029	1,165	-	-	-	900	-
Current Liabilities	-	3,826	-	-	2,870	2,642	1,637	1,029	1,165	467	1,475	1,473	900	992
Shareholder's Equity	-58.9%	-4,263	-2,682	-	3,046	5,860	8,787	11,182	13,352	11,962	13,025	15,344	2,013	822
Retained Earnings	-5.3%	-53,168	-50,506	-47,600	-44,072	-40,767	-35,341	-32,231	-29,194	-25,325	-22,752	-19,152	-16,832	-11,785
Additional Paid-In Capital	-21.9%	48,974	62,700	62,361	62,001	61,500	59,003	58,287	57,420	52,162	50,652	49,371	33,722	27,584
Shares Outstanding	2.3%	6,619	6,470	6,463	6,463	6,518	6,499	6,499	6,365	-	6,231	5,793	4,495	4,318

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2
Cashflow From Operations	-34.2%	-2,031	-1,513	-3,298	-2,235	-1,806	-2,344	-2,536	-1,562	-1,782	-2,046	-1,222	-1,257	-806	-442	-205	-
Share Based Compensation	-41.4%	187	318	369	491	1,508	716	867	1,258	1,131	1,280	740	297	575	654	506	-
Cashflow From Investing	-	-	-	-147	-	-	-	-	-	-	-	-	-	-	-	101	-
Cashflow From Financing	-	2,114	-	-	200*	-	-	-	3,942	400*	700*	14,912	3,146	841	386	77.00	-

ALZN Income Statement

2024-01-31

Condensed Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Jan. 31, 2024	Jan. 31, 2023	Jan. 31, 2024	Jan. 31, 2023
OPERATING EXPENSES
Research and development	$ 1,908,757	$ 2,888,847	$ 6,271,677	$ 5,797,789
General and administrative	751,173	2,534,665	2,815,904	5,767,668
Total operating expenses	2,659,930	5,423,512	9,087,581	11,565,457
Loss from operations	(2,659,930)	(5,423,512)	(9,087,581)	(11,565,457)
OTHER EXPENSE, NET
Interest expense	(2,488)	(2,062)	(8,636)	(7,182)
Total other expense, net	(2,488)	(2,062)	(8,636)	(7,182)
NET LOSS	$ (2,662,418)	$ (5,425,574)	$ (9,096,217)	$ (11,572,639)
Basic net loss per common share	$ (0.38)	$ (0.83)	$ (1.35)	$ (1.78)
Diluted net loss per common share	$ (0.38)	$ (0.83)	$ (1.35)	$ (1.78)
Basic weighted average common shares outstanding	7,054,319	6,555,078	6,726,926	6,517,698
Diluted weighted average common shares outstanding	7,054,319	6,555,078	6,726,926	6,517,698

ALZN Balance Sheet

2024-01-31

Condensed Balance Sheets (Unaudited) - USD ($)	Jan. 31, 2024	Apr. 30, 2023
CURRENT ASSETS
Cash	$ 282,867	$ 5,140,859
Prepaid expenses and other current assets	310,738	447,589
Prepaid expenses - related party		247,334
TOTAL CURRENT ASSETS	593,605	5,835,782
Property, plant and equipment, net	189,031	79,843
TOTAL ASSETS	782,636	5,915,625
CURRENT LIABILITIES
Accounts payable and accrued liabilities	3,826,457	2,870,122
TOTAL CURRENT LIABILITIES	3,826,457	2,870,122
LONG-TERM LIABILITIES
Warrant liability	742,263
TOTAL LIABILITIES	4,568,720	2,870,122
MEZZANINE EQUITY
Series B Convertible Preferred Stock, $0.0001 stated value per share, 6,000 shares designated; 1,220 and nil 0 issued and outstanding as of January 31, 2024 and April 30, 2023, respectively	477,737
STOCKHOLDERS’ (DEFICIT) EQUITY
Common stock, $0.0001 par value: 300,000,000 shares authorized; 6,618,766 and 6,462,675 issued and outstanding as of January 31, 2024 and April 30, 2023, respectively	662	646
Additional paid-in capital	48,974,396	62,000,814
Note receivable for common stock – related party		(14,883,295)
Subscription receivable for preferred stock – related party	(70,000)
Accumulated deficit	(53,168,879)	(44,072,662)
TOTAL STOCKHOLDERS’ (DEFICIT) EQUITY	(4,263,821)	3,045,503
TOTAL LIABILITIES MEZZANINE AND STOCKHOLDERS’ (DEFICIT) EQUITY	782,636	5,915,625
Series A Preferred Stock [Member]
STOCKHOLDERS’ (DEFICIT) EQUITY
Preferred stock, Value

About Alzamend Neuro, Inc.

Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.

CEO	Mr. Stephan Jackman
WEBSITE	alzamend.com
INDUSTRY	Biotechnology
EMPLOYEES	4

Alzamend Neuro, Inc. Frequently Asked Questions

What is the ticker symbol for Alzamend Neuro, Inc.? What does ALZN stand for in stocks?

ALZN is the stock ticker symbol of Alzamend Neuro, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Alzamend Neuro, Inc. (ALZN)?

As of Wed Apr 24 2024, market cap of Alzamend Neuro, Inc. is 4.88 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ALZN stock?

You can check ALZN's fair value in chart for subscribers.

What is the fair value of ALZN stock?

You can check ALZN's fair value in chart for subscribers. The fair value of Alzamend Neuro, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Alzamend Neuro, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ALZN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Alzamend Neuro, Inc. a good stock to buy?

The fair value guage provides a quick view whether ALZN is over valued or under valued. Whether Alzamend Neuro, Inc. is cheap or expensive depends on the assumptions which impact Alzamend Neuro, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ALZN.